A citation-based method for searching scientific literature

Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Circulation 2019
Times Cited: 261



Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, Christopher P Cannon, George Capuano, Pei-Ling Chu, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Gary Meininger, Barry M Brenner, Kenneth W Mahaffey. N Engl J Med 2019
Times Cited: 1536




List of shared articles



Times cited


Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021
8

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
90

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
37

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Emily Brown, John P H Wilding, Uazman Alam, Thomas M Barber, Janaka Karalliedde, Daniel J Cuthbertson. Ann Med 2021
2

Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.
Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Jenssen. Transpl Int 2021
6

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
John J V McMurray, David C Wheeler, Bergur V Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Claes Held, Fan-Fan Hou,[...]. Circulation 2021
17

The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Daniel V O'Hara, Thomas R Parkhill, Sunil V Badve, Min Jun, Meg J Jardine, Vlado Perkovic. Diabetes Obes Metab 2021
3



Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Elisabetta Patorno, Ajinkya Pawar, Lily G Bessette, Dae H Kim, Chintan Dave, Robert J Glynn, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim. Diabetes Care 2021
6

Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Marta Baviera, Stefano Genovese, Vito Lepore, Pierluca Colacioppo, Fabio Robusto, Mauro Tettamanti, Antonio D'Ettorre, Fausto Avanzini, Ida Fortino, Antonio Nicolucci,[...]. Diabetes Obes Metab 2021
0

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
Avivit Cahn, Itamar Raz, Lawrence A Leiter, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L Bhatt, Darren K McGuire,[...]. Diabetes Care 2021
4

Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Muhammad Imtiaz Ahmad, Michael D Shapiro. Curr Atheroscler Rep 2021
1

Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis.
Dario Giugliano, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito. Diabetes Obes Metab 2021
3


Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
1


Role of newer antidiabetic drugs on cardiovascular prevention and heart failure.
Jesús Miguel Rojas-Velázquez, Alejandro Giralt-Herrera, Jessica Leiva-Enríquez, Jennifer Leiva-Enríquez. Clin Investig Arterioscler 2021
0

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P Dwyer, Hiddo H J L Heerspink, Avivit Cahn, Erica L Goodrich, Kyungah Im, Deepak L Bhatt, Lawrence A Leiter,[...]. JAMA Cardiol 2021
0


Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul,[...]. Eur Cardiol 2021
0

Contemporary Medical Management of Peripheral Artery Disease.
Marc P Bonaca, Naomi M Hamburg, Mark A Creager. Circ Res 2021
1

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
Emily Brown, Hiddo J L Heerspink, Daniel J Cuthbertson, John P H Wilding. Lancet 2021
5

Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Adam J Nelson, Neha J Pagidipati, Vanita R Aroda, Matthew A Cavender, Jennifer B Green, Renato D Lopes, Hussein Al-Khalidi, Tanya Gaynor, Lisa A Kaltenbach, Julienne K Kirk,[...]. Circulation 2021
0


Management of type 2 diabetes in chronic kidney disease.
Jefferson L Triozzi, L Parker Gregg, Salim S Virani, Sankar D Navaneethan. BMJ Open Diabetes Res Care 2021
0

Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021.
José Carlos Nicolau, Gilson Soares Feitosa Filho, João Luiz Petriz, Remo Holanda de Mendonça Furtado, Dalton Bertolim Précoma, Walmor Lemke, Renato Delascio Lopes, Ari Timerman, José A Marin Neto, Luiz Bezerra Neto,[...]. Arq Bras Cardiol 2021
0

Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021).
Francisco Arrieta, Juan Pedro-Botet, Pedro Iglesias, Juan Carlos Obaya, Laura Montanez, Gonzalo Fernando Maldonado, Antonio Becerra, Jorge Navarro, J C Perez, Romina Petrecca,[...]. Clin Investig Arterioscler 2021
0

Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Lei Tian, Yuzi Cai, Huijuan Zheng, Sinan Ai, Mengqi Zhou, Qian Luo, Jingyi Tang, Weijing Liu, Yaoxian Wang. Front Pharmacol 2021
0


ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes.
Edoardo Gronda, Claudio Napoli, Massimo Iacoviello, Stefano Urbinati, Pasquale Caldarola, Edoardo Mannucci, Furio Colivicchi, Domenico Gabrielli. Eur Heart J Suppl 2021
0